Supplementary Figure S7 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Authors:Helen D. Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen et al.
<jats:p><p>Longitudinal analysis of CBC and liver function post-treatment. (A) Total eosinophil (B) platelet and (C) lymphocyte counts quantified at days 0, 2, 4, 8, 15, 22, and 29 post-treatment (n = 3–5 per group). (D) Liver function assessed through the analysis of AST, ALT, and GGT levels over time at the same intervals (n = 3–5 per group). Data are expressed as mean ± SEM.</p></jats:p>
Keywords
analysisliverfunctionposttreatmentgroup
Related Articles
Supplementary Figure 9 from Targeting the NAD<sup>+</sup> Salvage Pathway Blocks Metabolic Recovery and Enhances β-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells
Bruce Chang-Gu, Tuvshintugs Baljinnyam et al. - Unknown
Supplementary Figure S4 from <i>SPEN</i> Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Supplementary Data S1 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
Marie-Anne Goyette, Christopher Graser et al. - Unknown
Supplementary Data 2 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Helen D. Clark, Samira Aghlara-Fotovat et al. - Unknown